Ulrich Krauss to succeed Analytik Jena founder Klaus Berka as CEO
Analytik Jena
The succession plan, supported by the Swiss parent company Endress+Hauser, was initiated back in the fall of 2015 to provide a smooth transition for the planned departure of the Company’s founder and his successor in the role of Chief Executive Officer. “We want to continue to develop Analytik Jena under the Endress+Hauser umbrella in the long term. Mr. Berka has successfully built up the Company over a
period of many years. On this basis, Mr. Krauss is well positioned to lead the Company into a successful future,” says Matthias Altendorf, CEO of the Endress+Hauser Group.
With the expansion of the Executive Board in the fall of 2015, the generational shift in the Company’s leadership was begun and the course set for the further development of Analytik Jena. “Our goal from the very beginning was to find a future-orientated succession plan,” says outgoing Chief Executive Officer Klaus Berka. With his extensive experience, he remains connected to the Company with his move to the Supervisory Board.
Ulrich Krauss (52) has been a member of the Executive Board at Analytik Jena since November, 2015, and brings more than two decades of experience in various international management positions at the Carl Zeiss Group. He had been a member of the Executive Board of Carl Zeiss Meditec AG in Jena for more than nine years before leaving in 2011 and most recently held the position of CEO at Carl Zeiss Vision, Inc., in the US before coming to Analytik Jena.
“Analytik Jena is a very customer-focused technology company in an exciting and expanding industry. In the new Executive Board team, we want to continue the successful development that this Company has achieved over the past 26 years and expand on it. I am inspired by the expertise and high motivation of our employees and the potential for further, profitable growth,” says Ulrich Krauss.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.